Our Mission

New Release: ProFine®

ProFine® is now available at our online store as well as at www.Amazon.com.

ProFine® Description:

New STTR grant

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This grant is to support the research on a potent small-molecule compound and its use in treating bone metastatic castration-resistant prostate cancer.

New STTR grant

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound in treating prostate cancer.

Phase I STTR grant supporting ProFine® study

MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine® in enhancing standard prostate cancer therapy.